Ethypharm DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Lead Product(s) : Argatroban Monohydrate,Inapplicable

Therapeutic Area : Hematology

Highest Development Status : Approved FDF

Recipient : Mitsubishi Tanabe Pharma

Deal Size : Undisclosed

Deal Type : Acquisition

Acquisition of Argatroban Business in Europe

Details : Ethypharm acquired Mitsubishi Tanabe's selective antithrombin agent Arganova (argatroban monohydrate) in Europe. It is indicated for the treatment of heparin-induced thrombocytopenia type II.

Product Name : Arganova

Product Type : Miscellaneous

Upfront Cash : Undisclosed

June 17, 2024

02 Ethypharm

France

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Lead Product(s) : Mesalazine,Inapplicable

Therapeutic Area : Immunology

Highest Development Status : Approved FDF

Recipient : Anbison

Deal Size : Undisclosed

Deal Type : Acquisition

Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

Details : The acquisition will enable Ethypharm a full portfolio of Mesalazine forms, including a suppository form of Etiasa (mesalazine), used to treat IBD such as ulcerative colitis and Crohn's disease.

Product Name : Etiasa

Product Type : Miscellaneous

Upfront Cash : Undisclosed

June 13, 2024

03 Ethypharm

France

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Lead Product(s) : Morphine Sulfate,Inapplicable

Therapeutic Area : Neurology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Ethypharm Gains EU Approval for Morphine Immediate Release Tablets

Details : Company received marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine, an opioid receptor agonist for the management of severe pain.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

December 02, 2021

04 Ethypharm

France

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Lead Product(s) : Celecoxib,Inapplicable

Therapeutic Area : Neurology

Highest Development Status : Approved FDF

Recipient : Dr. Reddy\'s Laboratories

Deal Size : Undisclosed

Deal Type : Acquisition

Ethypharm Reinforces its Late-Stage R&D Pipeline with a Novel Acute Treatment of Migraine

Details : Ethypharm has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. Celecoxib is developed by D...

Product Name : Elyxyb

Product Type : Miscellaneous

Upfront Cash : Undisclosed

May 19, 2021

05 Ethypharm

France

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Lead Product(s) : Vigabatrin,Inapplicable

Therapeutic Area : Neurology

Highest Development Status : Approved FDF

Recipient : Orphelia Pharma

Deal Size : Undisclosed

Deal Type : Licensing Agreement

ORPHELIA, Ethypharm Sign Kigabeq® Licensing Deal for China

Details : Orphelia has granted Ethypharm exclusive rights under a license agreement to commercialize Kigabeq (vigabatrin) in China. Kigabeq is indicated as a first-line treatment for infantile spasms.

Product Name : Kigabeq

Product Type : Miscellaneous

Upfront Cash : Undisclosed

January 19, 2021

06 Ethypharm

France

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Lead Product(s) : Triamcinolone Acetonide,Inapplicable

Therapeutic Area : Immunology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Medexus Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH...

Details : Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales ...

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Undisclosed

December 18, 2020

07 Ethypharm

France

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Lead Product(s) : Cholic Acid,Inapplicable

Therapeutic Area : Genetic Disease

Highest Development Status : Approved FDF

Recipient : Laboratoires CTRS

Deal Size : Undisclosed

Deal Type : Agreement

Ethypharm, CTRS Partner to Register Orphacol® in China

Details : Under the agreement, CTRS has granted Ethypharm exclusive rights to distribute Orphacol (cholic acid) in China. It is indicated for the two rare inborn errors of primary bile acid synthesis.

Product Name : Orphacol

Product Type : Miscellaneous

Upfront Cash : Undisclosed

November 10, 2020

08 Ethypharm

France

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Lead Product(s) : Fentanyl,Inapplicable

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Undisclosed

Recipient : Reading Scientific Services

Deal Size : Undisclosed

Deal Type : Partnership

Ethypharm and RSSL Fast-Track Medicine for COVID-19 Patients

Details : The collaboration is intended to accelerate the manufacture and batch release of fentanyl injection; one of the critical medicines needed for the treatment of COVID-19 patients.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Undisclosed

June 04, 2020